Real-world studies have confirmed these results: a 2025 study published in Diabetes, Obesity and Metabolism found tirzepatide was associated with greater weight loss over 6 months than semaglutide in patients without diabetes, consistent with the trial data
obesity) Prior authorization requirements Step therapy requirements State mandates Cost-Effectiveness Despite higher efficacy, tirzepatide is similarly priced to semaglutide, potentially offering better value per pound lost
Kinoshita M, Ogawa Y, Hama N, Ujiie I, Hasegawa A, Nakajima S, et al
Additionally, it slows down the emptying of the stomach, leading to a feeling of fullness and reduced appetite